对454项使用皮肤病生活质量指数的随机对照试验的系统综述:涵盖69种疾病和43个国家的经验
该系统综述遵循PRISMA指南,检索7个文献数据库1994年1月1日至2021年11月16日的文献,最终纳入454项随机对照试验、涉及198 190例患者。DLQI在5.3%的研究中作为主要终点,研究最多的疾病为银屑病(54.1%),多数干预为系统性药物(85.1%)。Jadad量表显示偏倚总体较低,91.8%的研究Jadad评分≥3。
要点
- DLQI在454项随机对照试验中应用,覆盖69种疾病和至少42个国家。
- 仅5.3%的研究将DLQI作为主要终点,15.0%的研究报告了最小临床重要差值。
- 91.8%的研究Jadad评分≥3, randomization偏倚高风险仅0.4%。
核心结论
- 该系统综述提供了DLQI在临床试验中应用的大量证据,为研究者和临床医生进一步使用DLQI提供决策参考,并对未来使用DLQI的随机对照试验数据报告提出改进建议。
研究设计与样本
- 遵循PRISMA指南的系统综述,检索7个文献数据库1994年1月1日至2021年11月16日发表的文献,由两名评估者独立审阅并由仲裁者解决分歧。
- 共筛选3220篇文献,最终纳入454项符合标准的随机对照试验,涉及198 190例患者。
主要发现
- DLQI在24项(5.3%)研究中作为主要终点。
- 研究最多的疾病为银屑病(54.1%),共涉及69种不同疾病。
- 多数研究药物为系统性药物(85.1%),其中生物制剂占所有药物干预的55.9%;局部治疗占药物干预的17.0%;非药物干预(主要为激光治疗和紫外线照射治疗)占干预总数的12.2%。
- 63.7%的研究为多中心研究,试验至少在42个不同国家开展,40.2%为多国开展。
- 15.0%的研究在分析中报告了最小临床重要差值(MCID),仅1.3%的研究考虑了DLQI完整评分意义分带。
关键数值与推荐
- DLQI作为主要终点的研究比例为5.3%(24项)。
- 银屑病研究占54.1%;系统性药物占85.1%,生物制剂占药物干预的55.9%,局部治疗占17.0%,非药物干预占12.2%。
- 多中心研究占63.7%;至少42个国家开展试验,40.2%为多国研究。
- 报告MCID的研究占15.0%,考虑完整评分意义分带的研究仅1.3%。
- Jadad评分≥3的研究占91.8%;随机化高偏倚风险0.4%,盲法高偏倚风险13%,所有参与者结局未知高偏倚风险10.1%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Over 29 years of clinical application, the Dermatology Life Quality Index (DLQI) has remained the most used patient-reported outcome (PRO) in dermatology due to its robustness, simplicity and ease of use. OBJECTIVES: To generate further evidence of the DLQI's utility in randomized controlled trials (RCTs) and to cover all diseases and interventions. METHODS: The methodology followed PRISMA guidelines and included seven bibliographical databases, searching articles published from 1 January 1994 until 16 November 2021. Articles were reviewed independently by two assessors, and an adjudicator resolved any opinion differences. RESULTS: Of 3220 screened publications, 454 articles meeting the eligibility criteria for inclusion, describing research on 198 190 patients, were analysed. DLQI scores were primary endpoints in 24 (5.3%) of studies. Most studies were of psoriasis (54.1%), although 69 different diseases were studied. Most study drugs were systemic (85.1%), with biologics comprising 55.9% of all pharmacological interventions. Topical treatments comprised 17.0% of total pharmacological interventions. Nonpharmacological interventions, mainly laser therapy and ultraviolet radiation treatment, comprised 12.2% of the total number of interventions. The majority of studies (63.7%) were multicentric, with trials conducted in at least 42 different countries; 40.2% were conducted in multiple countries. The minimal clinically importance difference (MCID) was reported in the analysis of 15.0% of studies, but only 1.3% considered full score meaning banding of the DLQI. Forty-seven (10.4%) of the studies investigated statistical correlation of the DLQI with clinical severity assessment or other PRO/quality of life tools; and 61-86% of studies had within-group scores differences greater than the MCID in 'active treatment arms'. The Jadad risk-of-bias scale showed that bias was generally low, as 91.8% of the studies had Jadad scores of ≥ 3; only 0.4% of studies showed a high risk of bias from randomization. Thirteen per cent had a high risk of bias from blinding and 10.1% had a high risk of bias from unknown outcomes of all participants in the studies. In 18.5% of the studies the authors declared that they followed an intention-to-treat protocol; imputation for missing DLQI data was used in 34.4% of studies. CONCLUSIONS: This systematic review provides a wealth of evidence of the use of the DLQI in clinical trials to inform researchers' and -clinicians' decisions for its further use. Recommendations are also made for improving the reporting of data from future RCTs using the DLQI.
引用
- Vyas J, Johns JR, Ali FM, et al. A systematic review of 454 randomized controlled trials using the Dermatology Life Quality Index: experience in 69 diseases and 43 countries. Br J Dermatol. 2024. PMID: 36971254. doi:10.1093/bjd/ljad079
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。